$0.38
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Mangoceuticals, Inc. engages in developing, marketing, and selling men's wellness products and services via a telemedicine platform. The company is headquartered in Dallas, Texas. The company went IPO on 2023-03-21. The company is advancing its proprietary antiviral compound MGX-0024. The firm offers pharmaceutical-based products specifically related to the treatments of erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management. The company has developed and is commercially marketing a brand of ED products under the brand name Mango; a brand of hair loss products under the brand name Grow; a brand of hormone balance and therapy products under the name Mojo, and a brand of weight loss products under the brand name Slim. Prime by MangoRx is a TRT product available by prescription. The Mango ED product includes the three ingredients: Either Sildenafil (the active ingredient in Viagra) or Tadalafil (the active ingredient in Cialis), and Oxytocin.
Country

US

CEO

Mr. Jacob Cohen

IPO date

2023

Employees

3

ISIN

US56270V2051

Key stats

Open

$0.39

Volume

1.15M

Market cap

$9.10M

Prev. close

$0.42

Impl / hst vl

-

Open interest

$0.00

$0.36

Day’s Range

$0.42

$0.16

52W Range

$1.25

Valuation

11
Valuation score
Strongly Overvalued
P/E
-
P/S
22.08
P/B
0.68
Current ratio
-
Debt / Equity
-
ROE
-
Gross margin
-
Income growth
-61.43%
FCF growth
-80.13

Analysts estimates

Earnings

Q2 ‘26 revenue
$68.80K
Q2 ‘26 net income
-$1.31M
Revenue
Net income
Previous EPS
-
Estimate EPS
$0.00
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply